BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Down 6.8% – Here’s What Happened

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT)’s share price dropped 6.8% on Friday . The stock traded as low as $8.21 and last traded at $8.2440. Approximately 111,990 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 280,972 shares. The stock had previously closed at $8.85.

Wall Street Analyst Weigh In

BBOT has been the topic of several recent research reports. Raymond James Financial upgraded BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research note on Friday, January 9th. Stifel Nicolaus initiated coverage on BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price target on the stock. Weiss Ratings initiated coverage on BridgeBio Oncology Therapeutics in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Finally, HC Wainwright upped their price target on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $26.00.

BridgeBio Oncology Therapeutics Price Performance

The business’s 50 day simple moving average is $9.86. The firm has a market cap of $672.25 million, a price-to-earnings ratio of -5.53 and a beta of 0.51.

Institutional Trading of BridgeBio Oncology Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $63,000. Persistent Asset Partners Ltd purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $107,000. Squarepoint Ops LLC purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $144,000. Quadrature Capital Ltd purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $162,000. Finally, BIT Capital GmbH purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $313,000. 54.89% of the stock is currently owned by hedge funds and other institutional investors.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.